Диссертация (Фибрилляции предсердий - предикторы прогрессирования, эволюция клинического течения и выбор стратегии лечения), страница 35
Описание файла
Файл "Диссертация" внутри архива находится в папке "Фибрилляции предсердий - предикторы прогрессирования, эволюция клинического течения и выбор стратегии лечения". PDF-файл из архива "Фибрилляции предсердий - предикторы прогрессирования, эволюция клинического течения и выбор стратегии лечения", который расположен в категории "". Всё это находится в предмете "медицина" из Аспирантура и докторантура, которые можно найти в файловом архиве МГМУ им. Сеченова. Не смотря на прямую связь этого архива с МГМУ им. Сеченова, его также можно найти и в других разделах. , а ещё этот архив представляет собой докторскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени доктора медицинских наук.
Просмотр PDF-файла онлайн
Текст 35 страницы из PDF
[et al.] //Ann InternMed – 2007- Vol 146- P.857–867171. He X. Atrial fibrillation induces myocardial fibrosis throughangiotensin II type 1 receptor-specific arkadia-mediated downregulation ofSmad. / He X. [et al.] // Circ Res.- 2011- Vol 108(2)- P.164–175.172. Healey JS. Prevention of atrial fibrillation with angiotensinconverting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis./Healey JS. [et al.] // J Am Coll Cardiol. - 2005 – vol 45(11)- P.1832-9.173. Heeringa J.
Prevalence, incidence and lifetime risk of atrialfibrillation: the Rotterdam study./ Heeringa J. [et al.] //Eur Heart J – 2006 -Vol27- P. 949 -953.174. Heijman J. Cellular and molecular electrophysiology of atrialfibrillation initiation, maintenance, and progression./ Heijman J.[et al.]//Circulation Research. – 2014- Vol 114(9)- P.1483–1499.175. Hindricks G. Performance of a new leadless implantable cardiacmonitor in detecting and quantifying atrial fibrillation — results of the EXPECT241trial.
/ Hindricks G. [et al.]// Circ Arrhythm Electrophysiol- 2010- Vol 3-P.141–147.176. Hobbs FR. European Primary Care Cardiovascular Society (EPCCS)consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primarycare. / Hobbs FR. [et al.] // Eur J Prev Cardiol – 2016- Vol 23-P. 460–473.177. Hohnloser SH. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial./Hohnloser SH. [et al.] // Lancet- 2000-Vol 356- P.1789-1794.178.
Holmqvist F. ORBIT-AF Investigators.Heart rate is associated withprogression of atrial fibrillation, independent of rhythm./ Holmqvist F. [et al.]//Heart.- 2015 – Vol 101(11)- P.894-9.179. Hou J, The impact of acute atrial fibrillation on the prothromboticstate in patients with essential hypertension./ Hou J. [et al.] // Clin Biochem.2010 – Vol 43(15)- P.1212-5.180. Iguchi Y. Relation of atrial fibrillation to glomerular filtration rate./Iguchi Y. [et al.] // Am J Cardiol – 2008 -Vol 102(8)-P.1056–9.181.
Im SI. Long-term Prognosis of Paroxysmal Atrial Fibrillation andPredictors for Progression to Persistnt or Chronic Atrial Fibrillation in the KoreanPopulation./ Im SI [et al.] // J Korean Med Sci. - 2015 – Vol 30(7)- P.895-902.182. Ionescu-Ittu R. Comparative effectiveness of rhythm control vs ratecontrol drug treatment effect on mortality in patients with atrial fibrillation /Ionescu-Ittu R. [et al.] // Arch Intern Med.- 2012- Vol 172-P. 997–1004.183. Israel C.W. Long-term risk of recurent atrial fibrillationasdocumented by implantable monitoring device: implications for optimal patientcare / Israel C.W. [et al.] // J Am Coll Cardiol- 2004-Vol 34- P.47—52184.
Iwasaki Y. Atrial fibrillation pathophysiology: implications formanagement / Iwasaki Y. [et al.] // Circulation -2011- Vol. 124- P. 2264–74.242185. Jahangir A. Long-term progression and outcomes with aging inpatients with lone atrial fibrillation: a 30-year follow-up study. / Jahangir A. [etal.] //Circulation – 2007- Vol 115- P. 3050–6.186.
Jahangir A. Progression of Paroxysmal to Persistent AtrialFibrillation: Factors Promoting the HATCH Score./ Jahangir A. [et al.] // Journalof the American College of Cardiology. – 2010- Vol 55(8)- P.732–734187. January CT American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guidelinefor the management of patients with atrial fibrillation: a report of the AmericanCollege of Cardiology/American Heart Association Task Force on PracticeGuidelines and the Heart Rhythm Society. / January CT. [et al.] // J Am CollCardiol.-2014- Vol 64(21)- P.1-76.188. Jibrini MB.
Prevention of atrial fibrillation by way of abrogation ofthe renin-angiotensin system: a systematic review and meta-analysis. / Jibrini MB[et al.] //Am J Ther. -2008 – Vol 15(1)- P.36-43.189. John B. Electrical remodelling of the left and right atria due torheumatic mitral stenosis./ John B [et al.]// Eur Heart J. – 2008- Vol 29(18)-P.2234-43.190. Kalus JS. The impact of suppressing the renin-angiotensin system onatrial fibrillation./ Kalus JS [et al.] // J Clin Pharmacol.
- 2006 – Vol 46(1)- P.218.191. Kannel WB. Prevalence, incidence, prognosis, and predisposingconditions for atrial fibrillation: population-based estimates. / Kannel WB. [et al.]//Am J Cardiol. - 1998 – Vol 82(8A), P.2-9.192. Kerr CR. Progression to chronic atrial fibrillation after the initialdiagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry ofAtrial Fibrillation./ Kerr CR.
[et al.] // Am Heart J -2005-Vol 149-P.489–96.243193. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid WorkGroup. KDIGO Clinical Practice Guideline for Lipid Management in ChronicKidney Disease. // Kidney Int- 2013 –Vol 3- P.1-305.194. Kirchhof P. Comprehensive risk reduction in patients with atrialfibrillation: emerging diagnostic and therapeutic options—a report from the 3rdAtrial Fibrillation Competence NETwork/European Heart Rhythm Associationconsensus conference./ Kirchhof P. [et al.] // Europace -2012Vol 14- P.8–27.195.
Kirchhof P. Hypertension begets hypertrophy begets atrialfibrillation? Insights from yet another sheep model. / Kirchhof P. [et al.]//EurHeart J. -2006 –Vol 27(24)- P.2919-20.196. Kirchhof P. Short-term versus long-term antiarrhythmic drugtreatment after cardioversion of atrial fibrillation (Flec-SL): a prospective,randomised, open-label, blinded endpoint assessment trial / Kirchhof P. [et al.]// Lancet. -2012-Vol 380-P.
238–246.197. Kirchhof P. Outcome parameters for trials in atrial fibrillation:executive summary. Recommendations from a consensus conference organizedby the German Atrial Fibrillation Competence NETwork (AFNET) and theEuropean Heart Rhythm Association (EHRA). /Kirchhof P. [et al.] // Eur Heart J-2007-Vol 28- P.2803–2817198. Kirchhof P. Early and comprehensive management of atrialfibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference onatrial fibrillation entitled ‘research perspectives in atrial fibrillation. /Kirchhof P.[et al.] //Europace – 2009-Vol 11-P.860—885.199. Kirchhof, P.
A roadmap to improve the quality of atrial fibrillationmanagement: proceedings from the fifth Atrial Fibrillation Network/EuropeanHeart Rhythm Association Consensus Conference. / Kirchhof P. [et al.]//Europace. – 2016Vol 18- P.37–50.200. Kistler P. Atrial electrical and structural abnormalities in an ovinemodel of chronic blood pressure elevation after prenatal corticosteroid exposure:244implications for development of atrial fibrillation / Kistler P. [et al.] // Eur. HeartJ.
– 2006. – Vol. 27 – P. 3045–3056.201. Kozlowski D. Lone atrial fibrillation: what do we know?/ KozlowskiD. [et al.] //Heart.- 2010- Vol 96(7)- P.498–503.202. Krahn AD. The natural history of atrial fibrillation: incidence, riskfactors, and prognosis in the Manitoba Follow-Up Study. / Krahn AD [et al.] //Am J Med. -1999 – Vol 98(5)- P.476-84.203. Kumai Y. FSR Investigators. Proteinuria and clinical outcomes afterischemic stroke. / Kumai Y [et al.] // Neurology -2012-Vol 78- P. 1909-15.204. Kumar AP.
Statins downregulate myeloperoxidase gene expressionin macrophages./ Kumar AP [et al.]// Biochem Biophys Res Commun- 2005-Vol331- P.442-51.205. Kunisek J. The prevalence of supraventricular arrhythmias withregard to the type and degree of left ventricular hypertrophy in patients withhypertensive heart disease.
/ Kunisek J. [et al.]// Wien Klin Wochenschr.- 2008Vol 120 -P.171-7.206. L’AllierPL.Angiotensin-convertingenzymeinhibitioninhypertensive patients is associated with a reduction in the occurrence of atrialfibrillation. / L’Allier PL. [et al.]//J Am Coll Cardiol. -2004 –Vol 44(1)- P.15964.207. Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythmafter cardioversion of atrial fibrillation / Lafuente-Lafuente C. [et al.]// CochraneDatabase Syst Rev. -2012- Vol 5-P.5049-5051.208. Laszlo R. Effects of selective mineralocorticoid receptor antagonismon atrial ion currents and early ionic tachycardia-induced electrical remodelling inrabbits.
/ Laszlo R. [et al.]//Naunyn Schmiedebergs Arch Pharmacol. - 2010 Vol382(4)- P.347-56.245209. Le Heuzey J.Y. The RecordAF study: design, baseline data, andprofile of patients according to chosen treatment strategy for atrial fibrillation. /Le Heuzey J.Y. [et al.] //Am J Cardiol – 2010- Vol 105(5)-P.687-30.210. Lemoine MD. Electrophysiological basis for atrial arrhythmia in aLong QT Syndrome mouse model. / Lemoine MD. [et al.] // Circulation. -2010Vol 122(1)-P.11401.211.
